Epirubicin extravasation: consequences of delayed management

BMJ Case Rep. 2017 Jan 6:2017:bcr2016218012. doi: 10.1136/bcr-2016-218012.

Abstract

Epirubicin is an anthracycline chemotherapy agent used for treatment of several cancers including oesophageal, breast and gastric. Extravasation is a well-recognised and serious complication of any intravenous therapies but especially chemotherapeutic agents. Signs of the injury can be subtle and without prompt recognition and treatment there can be extensive tissue damage and depending on location of injury this can result in significant functional loss. In this article, a case of delayed management of epirubicin extravasation from a cannula situated at the dorsum of the hand is discussed. Successful surgical reconstruction of the resulting substantial tissue damage using a radial forearm flap 21 days following injury is described.

Publication types

  • Case Reports

MeSH terms

  • Aftercare
  • Aged
  • Antibiotics, Antineoplastic / administration & dosage
  • Antibiotics, Antineoplastic / adverse effects*
  • Epirubicin / administration & dosage
  • Epirubicin / adverse effects*
  • Esophageal Neoplasms
  • Extravasation of Diagnostic and Therapeutic Materials / etiology
  • Extravasation of Diagnostic and Therapeutic Materials / surgery*
  • Female
  • Hand / surgery
  • Humans
  • Plastic Surgery Procedures
  • Skin Transplantation / methods
  • Surgical Flaps
  • Treatment Outcome

Substances

  • Antibiotics, Antineoplastic
  • Epirubicin